Latest Breaking News On - National medical products administration on - Page 7 : comparemela.com

Article summary Sinopharm, the Chinese pharmaceutical giant, has commenced phase-1 and phase-2 clinical trials for its new recombinant vaccine against COVID-19 in central China’s Henan province since Saturday. This is the CNBG’s third COVID-19 vaccine candidate approved for human trials Developed by the China National Biotec Group (CNBG), a Sinopharm’s bioscience subsidiary, the vaccine was issued with a clinical research permit from the National Medical Products Administration on April 9. READ MORE: Mainland reports 13 new COVID-19 cases, all imported This is the CNBG’s third COVID-19 vaccine candidate approved for human trials. Researchers started the early-staged clinical trials in the city of Shangqiu, Henan Province. The trials were randomized, double-blind and placebo-controlled, according to a company statement.

China national biotec groupNational medical products administration onNational medical products administrationசீனா தேசிய பயோடெக் குழு